Completed

NCT Number: NCT05715723

Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

Acute ethanol intoxication is the most frequent pathologic condition developing in subjects using alcohol. The severity of disorders in acute alcohol intoxication is determined, first of all, by the quantity of consumed alcohol and the duration of the toxic effect. When toxic doses of alcohol are taken per os, a life-threatening condition develops, which is manifested by consciousness depression and severe metabolism disorders. Reamberin (1.5 % meglumine sodium succinate solution) is an infusion solution with a balanced electrolyte composition and succinic acid, which is recommended for rehydration and detoxication in patients with intoxications of different genesis. The metabolic effect of Reamberin helps restore homeostasis and improve the natural organism detoxication. The investigators suppose that administration of Reamberin to patients with acute ethanol intoxication will make it possible to improve the treatment quality as compared to the standard therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ethanol Intoxication

Age range

22 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

City Clinical Hospital of Emergency Medical Care, Kaliningrad, Russia

About this study

All drugs will be administered according to the instruction for medical use and conventional clinical practice.

The decision on the selection of therapy shall be made by a medical investigator irrespective of the protocol before the inclusion of a patient in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female patients aged from 22 to 65 years.
It is planned to administer one of the following treatment types to the patient, as part of the routine clinical practice:

Standard fluid administration + Reamberin®. It is planned to administer the drug Reamberin® in the average daily dose of 10 ml/kg daily for the whole period of treatment at ICU.
Standard fluid administration (without the use of the drug Reamberin®).
Primary diagnosis:

toxic effect of ethanol (T51.0 according to ICD-10);
acute intoxication caused by the simultaneous use of several narcotic drugs and the use of other psychoactive substances2 (F19.0 according to ICD-10);
mental and behavioral disorders caused by alcohol use. Acute intoxication (F10.0 according to ICD-10).
Blood ethanol concentration: 1.5 ‰ (per mille) and more.
Consciousness depression (Glasgow Coma Score = 6-12)
Laboratory signs of a shift in the acid-base balance towards metabolic acidosis: base deficit (BE) of venous blood less than -2.2 mmol/l).
Availability of the written consent of the patient or his (her) legally authorized representative.

Exclusion criteria

Use of other drugs containing malate or succinate.
Consciousness depression with Glasgow Coma Score of lower than 6.
Intoxication with addictive substances and psychotropic drugs.
Shock.
Body weight of less than 50 kg or more than 120 kg.
Data on the presence of malignant neoplasms.
Decompensation of chronic pulmonary diseases with the development of respiratory failure of degree II-III as at the time of inclusion in the study.
Pregnancy, breast feeding.
Craniocerebral injury or polytrauma.
Acute cerebrovascular accident.
Infection-inflammatory disease of CNS (meningitis, encephalitis etc.) and other variants of CNS function disorder not associated with ethanol intoxication.
Respiratory impairment requiring ALV.
Contraindications mentioned in the approved instructions for the use of the drugs used in the study.
A disease or the use of drugs, which, in the physician's opinion, can influence safety, tolerance and efficiency of the study drugs.

Treatment and study plan

Reamberin

Drug

Reamberin® in the average daily dose of 10 ml/kg daily

Primary outcomes

Difference in the average stay duration at ICU between patient groups.

Time frame: Up to 2 weeks
Difference in the average consciousness recovery duration between patient groups.

Time frame: Up to 2 weeks

Secondary outcomes

Difference in average blood lactate levels between the groups, measured at the baseline and after 24 hours of the therapy

Time frame: Baseline, 24 hours after the intervention
Difference in average serum bicarbonate levels between the groups, measured at the baseline and after 24 hours of the therapy

Time frame: Baseline, 24 hours after the intervention
Percentage of patients, whose consciousness recovered to Glasgow Coma Score of up to 14 after 24 hours of the therapy, measured in both groups.

Time frame: 24 hours after the intervention

The Glasgow Coma Scale: 15 points - clear consciousness.

14-13 points - moderate stunning.

12-11 points - deep stunning.

10-8 points - sopor.

7-6 points - moderate coma.

5-4 points - deep coma.

3 points - terminal coma, brain death.
Dynamics of serum bicarbonate levels during the study (at the baseline, in 24 hours, by the end of the treatment in ICU), measured in both groups.

Time frame: Baseline, 24 hours after the intervention, up to 2 weeks
Dynamics of organ failure score according to SOFA scale during the study, measured in both groups.

Time frame: Baseline, 24 hours after the intervention, up to 2 weeks

Sepsis-related Organ Failure scale: min 0 points, max 24 points. The higher the total score, the higher the degree of multiple organ failure
Dynamics of consciousness level score according to Glasgow Coma Scale during the study, measured in both groups.

Time frame: Baseline, 24 hours after the intervention, up to 2 weeks

The Glasgow Coma Scale: 15 points - clear consciousness.

14-13 points - moderate stunning.

12-11 points - deep stunning.

10-8 points - sopor.

7-6 points - moderate coma.

5-4 points - deep coma.

3 points - terminal coma, brain death.
Dynamics of the total score according to ICDSC scale (Intensive Care Delirium Screening Checklist) during the study, measured in both groups

Time frame: Baseline, 24 hours after the intervention, up to 2 weeks

Intensive Care Delirium Screening Checklist: ыcore ≥ 4 - delirium
Percentage of patients, who developed delirium, measured in both groups

Time frame: Up to 2 weeks
Percentage of patients, who developed hospital-acquired pneumonia, measured in both groups

Time frame: Up to 2 weeks
Percentage of patients, who developed extrapulmonary complications, measured in both groups.

Time frame: Up to 2 weeks
Percentage of lethal outcomes for the whole study period, measured in both groups.

Time frame: Up to 2 weeks
Percentage of patients, for whom it became necessary to administer ALV, over the whole study period, measured in both groups.

Time frame: Up to 2 weeks

Sponsors and collaborators

Lead sponsor

POLYSAN Scientific & Technological Pharmaceutical Company

Industry

Registry information

Official study title

Non-interventional, Prospective Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication: Hospital Practice

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2025
First posted: Feb 8, 2023
Registry last updated: Apr 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

NCT05487404

Ethanol Intoxication

Cincinnati, Ohio, United States

View Trial Details

Completed

N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking

NCT05911282

Ethanol Intoxication

Ljubljana, Slovenia

View Trial Details

Key information

Conditions

Age range

Sex eligibility

Study type

Primary location

About this study

Who can participate

Treatment and study plan

Reamberin

Primary outcomes

Difference in the average stay duration at ICU between patient groups.

Difference in the average consciousness recovery duration between patient groups.

Secondary outcomes

Difference in average blood lactate levels between the groups, measured at the baseline and after 24 hours of the therapy

Difference in average serum bicarbonate levels between the groups, measured at the baseline and after 24 hours of the therapy

Percentage of patients, whose consciousness recovered to Glasgow Coma Score of up to 14 after 24 hours of the therapy, measured in both groups.

Dynamics of serum bicarbonate levels during the study (at the baseline, in 24 hours, by the end of the treatment in ICU), measured in both groups.

Dynamics of organ failure score according to SOFA scale during the study, measured in both groups.

Dynamics of consciousness level score according to Glasgow Coma Scale during the study, measured in both groups.

Dynamics of the total score according to ICDSC scale (Intensive Care Delirium Screening Checklist) during the study, measured in both groups

Percentage of patients, who developed delirium, measured in both groups

Percentage of patients, who developed hospital-acquired pneumonia, measured in both groups

Percentage of patients, who developed extrapulmonary complications, measured in both groups.

Percentage of lethal outcomes for the whole study period, measured in both groups.

Percentage of patients, for whom it became necessary to administer ALV, over the whole study period, measured in both groups.

Sponsors and collaborators

Lead sponsor

Registry information

Official study title

Important dates

Related clinical trials

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking